Update on triple therapy for eradication of Helicobacter pylori: current status of the art
Riccardo Urgesi,1 Rossella Cianci,2 Maria Elena Riccioni3
1Gastroenterology and Endoscopy Unit, Viterbo, 2Institute of Internal Medicine, Catholic University of Rome, 3Digestive Endoscopy Unit, Catholic University of Rome, Rome, Italy
Abstract: With the rising prevalence of antimicrobial resistance, the treatment success of standard triple therapy has recently declined to unacceptable levels (ie, 80% or less). Following the failure of conventional triple therapy, novel eradication regimens have been developed including sequential therapy, concomitant quadruple therapy, hybrid (dual-concomitant) therapy, bismuth-containing quadruple therapy, and a therapy with administration of N-acetylcysteine before a culture-guided antibiotic regimen. This article reviews the literature published on Helicobacter pylori eradication in the last year, focusing on the development of alternative strategies for first-, second-, and third-line rescue therapy for the eradication of H. pylori.
Keywords: sequential therapy, quadruple therapy, concomitant therapy, hybrid therapy, N-acetylcysteine
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.